Blainville – October 26, 2010. A new player has entered into the Canadian orphan drug landscape: Medunik Canada, with a mission to bring currently unavailable orphan therapies for Canadian individuals with rare diseases. Headquartered in the northern area of Montréal, Medunik Canada is the sister company of Duchesnay Inc., a specialty pharmaceutical company dedicated mainly to the health of pregnant women and their unborn babies. Duchesnay and Medunik Canada are part of the Groupe Pharmaceutique Boivin, a Canadian family-owned organisation.

On the occasion of the Spring 2010 meeting of the NORD Corporate Council held in Washington, DC, Éric Gervais, Medunik Canada's Executive Vice-President, delivered a speech before senior executives from more than 70 leading companies and organizations. He stressed that the creation of the new company Medunik Canada, represents the culmination of over 10 years of participation as a NORD Corporate Council member.